A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Trial Profile

A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs FT 1101 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors FORMA Therapeutics
  • Most Recent Events

    • 12 Jan 2016 First patient has been enrolled and dosed, according to a FORMA Therapeutics media release.
    • 18 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top